Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8496478 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8499359 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL791465 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8498124 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8500355 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8499737 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL12982429 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8496079 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8499231 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E | |
| SCHEMBL8499492 | 1.00 | L3MBTL1 (0.57) | L3MBTL1TDP1SIGMAR1IDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977795-A | Efficient chemical recovery method for waste polyester fabrics | 南亚塑胶工业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | disclosed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1227098-B1 | TRIAZOLOPURINE DERIVATIVES, DRUG COMPOSITIONS CONTAINING THE SAME AND ADENOSINE A3 RECEPTOR AFFINITIVE AGENTS | OTSUKA PHARMA CO LTD (JP) | 2004-04-28 | — | — | EP | disclosed |
| US-6686343-B1 | Triazolopurine derivatives, pharmaceutical compositions containing the derivatives, and adenosine A3 receptor affinitive agents | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-02-03 | — | — | US | disclosed |
| EP-1227098-A1 | TRIAZOLOPURINE DERIVATIVES, DRUG COMPOSITIONS CONTAINING THE SAME AND ADENOSINE A3 RECEPTOR AFFINITIVE AGENTS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| US-5952316-A | FOR TREATING AUTOIMMUNE DISEASES, E.G., RHEUMATIOD ARTHRITIS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | L3MBTL1 1503/4885TDP1 2138/4885SIGMAR1 4091/4885 |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | L3MBTL1 4871/4885TDP1 724/4885SIGMAR1 2629/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | L3MBTL1 1503/4885TDP1 2138/4885SIGMAR1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.